title: Insight and treatment outcome in obsessive-compulsive disorder.
abstract: To determine whether (1) insight in obsessive-compulsive disorder (OCD) improves when OCD symptoms improve, and whether (2) degree of insight in OCD predicts response to sertraline, data were obtained from five sites participating in a larger multisite study of relapse in OCD. During the first 16 weeks of the study, 71 patients received open-label treatment with sertraline and were assessed using the Yale-Brown Obsessive-Compulsive Rating Scale (Y-BOCS) and a rating scale to evaluate insight, the Brown Assessment of Beliefs Scale (BABS), at study baseline and termination. Baseline total BABS score was not significantly correlated with change in Y-BOCS score. Change in BABS total score and change in Y-BOCS total score were significantly correlated. There was no significant difference in mean endpoint Y-BOCS scores for patients with poor insight (n = 14) compared to patients with good insight at baseline (n = 57). Thus, insight improved with decrease in OCD symptom severity. Degree of insight at baseline did not predict response to sertraline, i.e., patients with poor insight were just as likely to respond to sertraline as patients with good insight.
authors.affiliation: Butler Hospital and the Department of Psychiatry and Human Behavior, Brown University School of Medicine, Providence, RI 02906, USA.
authors.forename: J L
authors.initials: JL
authors.lastname: Eisen
authors.forename: S A
authors.initials: SA
authors.lastname: Rasmussen
authors.forename: K A
authors.initials: KA
authors.lastname: Phillips
authors.forename: L H
authors.initials: LH
authors.lastname: Price
authors.forename: J
authors.initials: J
authors.lastname: Davidson
authors.forename: R B
authors.initials: RB
authors.lastname: Lydiard
authors.forename: P
authors.initials: P
authors.lastname: Ninan
authors.forename: T
authors.initials: T
authors.lastname: Piggott
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001364:Awareness; D005260:Female; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D020280:Sertraline / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline